Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by BehStreet on Jun 06, 2020 12:21pm
229 Views
Post# 31120127

My take.

My take.I agree 100% with "Algernon" on his take of SH, and I understand why users may wish to quit and move to other discussion boards as 80% of this feed is utter nonesense with zero substance. But, I also think that we shouldn't give up completely on StockHouse, there are many retail investors that lurk (railbirds that read but don't post), trying to scrape some honey from the bottom of the jar. As far as South Korea, I have stated in the past that results likely won't start pouring in til late July or August, or, maybe a complete cancellation. The lead investigator for Algernon is Dr. Dong Sik Jung, of Dong-A Hospital in Busan. Now, there's a few things here.. First, South Korea has been excellent at containment with zero new cases for weeks up until May 28 when 79 new cases shook the country. Of those 79, one (1) new case was in Busan, with the majority being in Seoul, where the outbreak took place in a nightclub. Since then, South Korea has been on lockdown. Secondly, the 40 patient SK trail, run by AGN's cro Novotech, is to test the effect of NP-120 on COVID-19 patients with "severe pneumonia". So, AGN's cro is running a trial in a city with one positive covid patient and they may not even have pneumonia. It is my opinion that South Korea is a bust, at least for now. It is also my opinion that that's not necessarily a bad thing. We now have clearance from Health Canada and the FDA, waiting on Australia which I believe will come this next week. Once all three are a go, we will then get a start date with the logistics of the 2b/3 trial. This is what the market wants to know, not if they can have the trial, but when and how. The company has already been in talks with doctors in the U.S. and it should be easy peasy in getting those first 100 patients enrolled. That will be a two week trial, once data comes back, and if positive (Chris seemed very confident it will in the last proactive interview) they will move right into a phase 3 study. This is what will make the price move up (if it happens) to dollars, not cents. The reward far outweighs the risk imo. This will also take months, not days and weeks. So if you have the patience and like the story, then buy these dips, or sit on you hands and watch the progress. If you don't "buy" the story and have too many doubts, then sell and move on, there are thousands of other stocks.

GL Longs
<< Previous
Bullboard Posts
Next >>